Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. - sprookjes - yvandenbroek - TriplyDB

Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.

Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.

http://www.wikidata.org/entity/Q33946973

about

Redox Modulations, Antioxidants, and Neuropsychiatric Disorders Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy Developmental and pathological angiogenesis in the central nervous system Nanoscale drug delivery systems and the blood-brain barrier Insights into the structural determinants required for high-affinity binding of chiral cyclopropane-containing ligands to α4β2-nicotinic acetylcholine receptors: an integrated approach to behaviorally active nicotinic ligands.A novel BK channel-targeted peptide suppresses sound evoked activity in the mouse inferior colliculus.Targeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders-an overview and advancements Developing Enhanced Blood-Brain Barrier Permeability Models: Integrating External Bio-Assay Data in QSAR Modeling Lead optimization studies of cinnamic amide EP2 antagonists New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations.Dual binding site and selective acetylcholinesterase inhibitors derived from integrated pharmacophore models and sequential virtual screening.Total flavonoid of Litsea coreana leve exerts anti-oxidative effects and alleviates focal cerebral ischemia/reperfusion injury.Brainpeps: the blood-brain barrier peptide database.Synthesis and profiling of a diverse collection of azetidine-based scaffolds for the development of CNS-focused lead-like libraries.In vitro cerebrovascular modeling in the 21st century: current and prospective technologies.Pharmacological and functional magnetic resonance imaging techniques in CNS drug discovery.Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system.Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery Glycyrrhetinic acid and E.resveratroloside act as potential plant derived compounds against dopamine receptor D3 for Parkinson's disease: a pharmacoinformatics study.Preclinical studies of the potent and selective nicotinic α4β2 receptor ligand VMY-2-95 Metabolic conversion of dietary flavonoids alters their anti-inflammatory and antioxidant properties Antitumor agents 288: design, synthesis, SAR, and biological studies of novel heteroatom-incorporated antofine and cryptopleurine analogues as potent and selective antitumor agents.Pharmacoinformatics approach for investigation of alternative potential hepatitis C virus nonstructural protein 5B inhibitors.Monitoring therapeutic monoclonal antibodies in brain tumor.Efficacy of cabazitaxel in mouse models of pediatric brain tumors Tuscan black kale sprout extract bioactivated with myrosinase: a novel natural product for neuroprotection by inflammatory and oxidative response during cerebral ischemia/reperfusion injury in rat.Tertiary Amine Pyrazolones and Their Salts as Inhibitors of Mutant Superoxide Dismutase 1-Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral Sclerosis.Can formulation and drug delivery reduce attrition during drug discovery and development-review of feasibility, benefits and challenges.Concurrent middle cerebral artery occlusion and intra-arterial drug infusion via ipsilateral common carotid artery catheter in the rat Nanoparticle transport across the blood brain barrier.Cerebral microdialysis in clinical studies of drugs: pharmacokinetic applications Interpretation of antibiotic concentration ratios measured in epithelial lining fluid.Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.Shuttle-mediated drug delivery to the brain.Delivery of drugs to the brain via the blood brain barrier using colloidal carriers.Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development.In vitro prediction of brain penetration - a case for free thinking?Strategies to assess blood-brain barrier penetration.Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research.

P2860

Q26774067-A3142EC8-D385-442A-918E-168421072982 Q26782756-4CF9B10C-F2D2-4E24-B507-47F1D75BC540 Q27023250-59CECBA4-D15C-4FAC-B1EB-D79A29E825E3 Q27026978-90827DE4-A94C-4920-9717-E91174C0E062 Q27671769-B4C18152-B53E-4F71-84E7-8A4A37DBEEF5 Q30362915-4D35C046-4B82-4857-BE00-BBD8599526B3 Q30393215-E72A4EBD-1999-4B2F-97BE-365D3F33C6AE Q30929535-E3F37CC6-5DD8-4100-97E6-8BFB4D571BFD Q33654575-F651AAA4-3CF2-4969-B53E-DCEEBD8AEB82 Q33792474-516D89A2-5639-4BC0-911B-3D8CB82969EA Q33890728-317727D6-D3A0-4C1C-803F-492AE09625C1 Q34095790-2FE0875F-7EDB-4317-AFDD-F8241E413B62 Q34243408-C7180997-9E09-4022-B478-9AF865A9A2F3 Q34361517-C2B98158-71F4-405B-9433-AEB2F601D69E Q34476565-FA2F6EEA-2ED7-4BE9-A2B1-A81B56C9FEBB Q34621233-A82F89DD-0364-48AF-A2B9-39F715C6D3C6 Q34722740-9480FF5A-17EA-4B04-B57F-496390AF2F58 Q34729209-8F3585A9-3865-4667-A985-1412D6BA3024 Q34770959-1F043A17-94A2-4D15-A3C7-8E015922861C Q35057548-A6DAC29E-A6B8-4DB3-8C14-8C6BD0EA88D9 Q35057887-2438A877-2A14-488B-9FD8-C7A1BC3549B0 Q35120345-70E8C401-73D4-4A7D-A6AC-ACA16E4088A7 Q35248674-7F1DFBEB-ACEA-4DD2-B597-EF78D64EE728 Q35498835-6152DE60-1A42-4A11-907A-64C9EBC8D3F7 Q35788771-D9476CBE-5FF8-4A4B-B57F-62B946B62F6B Q35834600-764E2C48-9CC4-4EC0-9F54-3DD0744A2323 Q35956262-B8AEAF93-D2C6-485E-8D21-83AA32CEA8E0 Q36111924-032A0030-5FB8-485A-849C-D67FA66B0BA9 Q36604997-D6DC425F-FD01-4545-8BC9-82EAB2EEAD4A Q36812347-22BCB6A2-C327-470E-A32F-6B5B28795B29 Q36872983-196C625D-751E-4AC1-ABBD-8806CB7BF012 Q36936597-295FC01E-66FE-4179-80C6-19D1D1834846 Q37207750-03B1A6A4-A198-4249-AE1F-5B357A8C264D Q37416147-D7FA5F2C-728E-47FD-BD8B-2F11B0A58D83 Q37896550-BB8E9644-C08E-4FEE-8474-303819574579 Q38007992-32B24F9B-3B8E-4F82-87AA-1DA319FAC134 Q38050217-00FDF43B-279A-497D-9331-4C3CF25C84EA Q38090652-06A683B8-F52B-42DB-A881-6754DA72771E Q38090672-61538FC6-B223-408D-8D69-65335036F64E Q38117056-9D52A275-8A4E-4BD6-ACE2-3515DF21FE2E

P2860

Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.

http://www.wikidata.org/entity/Q33946973

description

2005 nî lūn-bûn

@nan

2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Drug metabolism and pharmacoki ...... nervous system drug discovery.

@ast

Drug metabolism and pharmacoki ...... nervous system drug discovery.

@en

type

label

Drug metabolism and pharmacoki ...... nervous system drug discovery.

@ast

Drug metabolism and pharmacoki ...... nervous system drug discovery.

@en

prefLabel

Drug metabolism and pharmacoki ...... nervous system drug discovery.

@ast

Drug metabolism and pharmacoki ...... nervous system drug discovery.

@en

P1433

Q33946973-C073940E-F005-4038-9C8E-E3F819F9764D

P1476

Q33946973-1D2942AA-94DB-4BA9-AC63-4A528E23578D

P2093

Q33946973-62F9CFCD-BBA8-41E4-86D8-1D8BEB44A2F0

Q33946973-9FCB4548-E75C-448D-9D71-EA01478C839F

Q33946973-AFED492A-C5F7-4F0F-AF80-35B50CECF0B5

Q33946973-CBCEDCE5-3A84-49D1-8034-D15BEAAB79F4

P2860

Q33946973-00AFA939-CCE2-4DFF-9299-C51D6F2F16B1

Q33946973-012FDB81-9757-4142-A937-C3CCDA00086C

Q33946973-04214A37-C3F1-44A2-BCE8-3BC97598BC88

Q33946973-0621B11C-4A40-4AB7-A1BC-6C1228FB7E82

Q33946973-06ED4C1B-C13B-4606-BEB1-F0FF601F7284

Q33946973-0740CB9E-8E8D-4DB2-AC10-2055DB6D13A8

Q33946973-0C3A4122-DC63-4F8A-83D8-C6C1223D032E

Q33946973-0E0CF26B-7935-4E13-BF6E-F5EA6267E61E

Q33946973-116714DA-8886-4337-BF12-4A3F040168F0

Q33946973-17BD59B1-0422-47F6-A01C-3C41F1DC8983

P304

Q33946973-7836A011-3413-435C-8E7C-08B5092874A9

P31

Q33946973-72444867-9236-4C1E-809C-5D6D71CAD990

P356

Q33946973-65D94F8D-D8C8-4074-951A-AE28B3F09B55

P433

Q33946973-49A710D2-64D1-47C7-8836-DA0B7182F30F

P478

Q33946973-ED9AA0A0-2567-43F0-B3B8-D20D698DC6DE

P577

Q33946973-4DD02486-DFC9-491A-82E1-FA8BE93321CE

P5875

Q33946973-3F7E4E06-0E2B-4AB5-9D04-96DC7B5E1321

P698

Q33946973-1C1F378E-2CC5-4D9E-B1C4-CEB458BCDAF0

P921

Q33946973-2C43A5E8-B214-41F8-87B7-691DD168CF2C

P932

Q33946973-624B3EB9-2B6E-4869-AA94-FCF3627CEAA6

P356

NEURORX.2.4.554

P1433

P1476

Drug metabolism and pharmacoki ...... nervous system drug discovery.

@en

P2093

Alan M Palmer

http://www.w3.org/2001/XMLSchema#string

M Zeeshan Qaiser

http://www.w3.org/2001/XMLSchema#string

Mansoor Chishty

http://www.w3.org/2001/XMLSchema#string

Mohammad S Alavijeh

http://www.w3.org/2001/XMLSchema#string

P2860

The blood-brain barrier: bottleneck in brain drug development

Excitatory amino acid antagonists for acute stroke

Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site

The value of improving the productivity of the drug development process: faster times and better decisions

The blood-brain barrier: an overview: structure, regulation, and clinical implications

In silico predictions of drug solubility and permeability: two rate-limiting barriers to oral drug absorption.

A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke.

Increased dopamine release in the human amygdala during performance of cognitive tasks.

In silico prediction models for blood-brain barrier permeation.

Applications of high-throughput ADME in drug discovery.

P304

554-571

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1602/NEURORX.2.4.554

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7288557

http://www.w3.org/2001/XMLSchema#string

P698

16489365

http://www.w3.org/2001/XMLSchema#string

P921

blood–brain barrier

P932

1201315

http://www.w3.org/2001/XMLSchema#string